期刊
INTERNATIONAL JOURNAL OF CANCER
卷 148, 期 7, 页码 1695-1707出版社
WILEY
DOI: 10.1002/ijc.33363
关键词
CCNU; TMZ; glioblastoma; MGMT promoter methylation
类别
资金
- German Federal Ministry of Education and Research [01KG1005]
The CeTeG/NOA-09 trial demonstrated a survival benefit for glioblastoma patients with MGMT promoter methylation ratios >2 who received combined CCNU/TMZ therapy. The prognostic value of qMSP ratio, as well as the concordance of MGMT methylation results obtained by different methods, were evaluated. Different qMSP ratio cutoffs may impact treatment efficacy, with lower ratios potentially showing larger benefits from CCNU/TMZ therapy. Acceptable concordance rates were observed among different MGMT methylation assays, allowing for potential consideration of alternative methods for therapeutic decision-making.
The CeTeG/NOA-09 trial showed a survival benefit for combined CCNU/TMZ therapy in MGMT-promoter-methylated glioblastoma patients (quantitative methylation-specific PCR [qMSP] ratio > 2). Here, we report on the prognostic value of the MGMT promoter methylation ratio determined by qMSP and evaluate the concordance of MGMT methylation results obtained by qMSP, pyrosequencing (PSQ) or DNA methylation arrays (MGMT-STP27). A potential association of qMSP ratio with survival was analyzed in the CeTeG/NOA-09 trial population (n = 129; log-rank tests, Cox regression analyses). The concordance of MGMT methylation assays (qMSP, PSQ and MGMT-STP27) was evaluated in 76 screened patients. Patients with tumors of qMSP ratio > 4 showed superior survival compared to those with ratios 2-4 (P = .0251, log-rank test). In multivariate analysis, the qMSP ratio was not prognostic across the study cohort (hazard ratio [HR] = 0.88; 95% CI: 0.72-1.08). With different cutoffs for qMSP ratio (4, 9, 12 or 25), the CCNU/TMZ benefit tended to be larger in subgroups with lower ratios (eg, for cutoff 9: HR 0.32 for lower subgroup, 0.73 for higher subgroup). The concordance rates with qMSP were 94.4% (PSQ) and 90.2% (MGMT-STP27). Discordant results were restricted to tumors with qMSP ratios <= 4 and PSQ mean methylation rate <= 25%. Despite a shorter survival in MGMT-promoter-methylated patients with lower methylation according to qMSP, these patients had a benefit from combined CCNU/TMZ therapy, which even tended to be stronger than in patients with higher methylation rates. With acceptable concordance rates, decisions on CCNU/TMZ therapy may also be based on PSQ or MGMT-STP27.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据